3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 3
5
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
159
Carboplatin
147
Cisplatin
130
Pemetrexed
103
Paclitaxel
89
Nivolumab
71
Radiotherapy
69
Docetaxel
62
Erlotinib Hydrochloride
58
Gemcitabine
57
Etoposide
44
osimertinib
43
Bevacizumab
43
Cyclophosphamide
42
durvalumab
41
atezolizumab
35
Cetuximab
33
Radiosurgery
26
130-nm albumin-bound paclitaxel
26
fludarabine
23
Ipilimumab
23
Radiation
21
Magnetic Resonance Spectroscopy
21
Irinotecan
21
Taxes
20
Oxaliplatin
20
Fluorouracil
20
Gefitinib
19
Everolimus
19
Topotecan
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Tiragolumab
×
Thoracic
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled